Product Details
| Product Name:
DB07268 |
CAS No.:
929007-72-7 |
| Purity:
98.20% |
Supply Ability:
10g |
| Release date:
2025/10/26 |
Product Introduction
Bioactivity
| Name | DB07268 |
| Description | DB07268 is a potent and selective JNK1 inhibitor. It exhibits a strong affinity for the JNK1 enzyme, effectively inhibiting its activity and providing potential therapeutic benefits in conditions where JNK1 is implicated. This compound has demonstrated selective binding to JNK1 over other kinases, underscoring its specificity and promising application in targeted therapies. |
| Kinase Assay | Following 3T3L1 adipocyte serum-starvation and insulin stimulation, cell lysates containing protease inhibitors are clarified and then subjected to immunoprecipitation with anti-PIKfyve antibodies. Washed beads are mixed with 100 μM PtdIns and preincubated for 15 min with YM-201636 (100 nM) or vehicle in the assay buffer (50 mM Tris-HCl, pH 7.5, 1 mM EGTA and 10 mM MgCl2). The kinase assay (50 μL final volume) is carried out for 15 min at 37 °C with 15 μM ATP and [γ-32P]ATP (30 μCi). Lipids are extracted, spotted on TLC glass plates (250 μm), resolved by a chloroform/methanol/water/ammonia solvent system and detected by autoradiography[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (155.6 mM), Sonication is recommended.
|
| Keywords | JNK1 | JNK | Inhibitor | inhibit | DB-07268 | DB07268 | DB 07268 |
| Inhibitors Related | Urolithin B | Astragaloside IV | SKLB-163 | SP600125 | (-)-Bornyl acetate | Tanzisertib | Anisomycin | SR-3306 | (E)-Ferulic acid methyl ester | Bentamapimod | Ginsenoside Re | TCS JNK 5a |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Endoplasmic Reticulum Stress Compound Library | Anti-Diabetic Compound Library | Kinase Inhibitor Library | Pyroptosis Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2470242-33-0
$63.00 / 5mg
-
CAS:76748-86-2
$29.00 / 10mg
-
CAS:1783816-74-9
$44.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States